Wikipedia -WSS

Wikipedia

author：comprehensive 2025-10-01 18:07:52 - browse：567

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： How many hemophilia patients actually want gene therapy?

explore

hotspot

WSS

Resistance to opioid

AMAs digital advisors table RPM coding reform proposal, again

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

First U.S. drug developed to treat liver disease MASH is approved

Male and female sex labels in research insufficient, scientists say

Abbott's new heart device gets FDA advisory panel nod

leisure time

Wikipedia

focus

Medicare details structure of new drug price negotiation program

Congress must protect the remaining independent doctors

Heart attack and stroke risk calculators need revising

Artificial intelligence use in health care faces greater scrutiny in 2024

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

UCLA team creates talking throat patch for voice disorders

At least 13 dead in Texas as scorching temps continue

Too many hospitalized Covid

Peter Hotez and the public health issue of online harassment

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

focus

First U.S. drug developed to treat liver disease MASH is approved

Why scientists need input from humanists on sensitive research

How many hemophilia patients actually want gene therapy?

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

knowledge

explore

hotspot

knowledge